Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770071 | 0.93 | — | — | |
| SCHEMBL772365 | 0.86 | PDE4B (0.34) | ALDH1A1POLB | |
| SCHEMBL770696 | 0.82 | MEN1 (0.38) | ALDH1A1POLB | |
| SCHEMBL770768 | 0.80 | ITGB3 (0.41) | ALDH1A1 | |
| SCHEMBL770381 | 0.80 | ITGB3 (0.41) | ALDH1A1POLB | |
| SCHEMBL771656 | 0.78 | MAPK1 (0.36) | ALDH1A1POLB | |
| SCHEMBL770758 | 0.78 | SMN1; SMN2 (0.39) | ALDH1A1POLB | |
| SCHEMBL2824310 | 0.78 | RAB9A (0.35) | ALDH1A1POLB | |
| SCHEMBL2938032 | 0.78 | RAB9A (0.35) | ALDH1A1POLB | |
| SCHEMBL770666 | 0.78 | RBP4 (0.44) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524894-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | ALDH1A1 142/4885POLB 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.